Mylan Launches MS Drug Generic Amid Biogen Patent Fight
Mylan launched its generic version of Biogen's $4 billion-a-year multiple sclerosis drug Tecfidera on Wednesday, capitalizing on a patent invalidation that cut Biogen's exclusivity period short by eight years....To view the full article, register now.
Already a subscriber? Click here to view full article